Skydance Reaches Deal to Merge With Paramount

The article presents a method for screening stocks to achieve increasing lifetime income, highlighting five Dividend Aristocrats that can contribute to this goal. It shares an inspiring success story of a retail investor who transformed a $180 investment into a remarkable $7 million windfall. The stock prices referenced are from April 13, 2025, and the video related to the content was published on April 15, 2025, with a note that Dividend Aristocrats® is a registered...

Despite a challenging year for stocks, Altria Group (MO -0.40%) has seen a nearly 10% increase in value, making it a reliable stock in volatile markets. Altria benefits from a stable nicotine demand, high profit margins, and strong market share, allowing for a robust 7% dividend yield and significant cash flow, despite meager top-line growth. While facing long-term threats from non-combustible products, Altria's adaptability and cash generation position it as a solid investment for mitigating...

The S&P 500 fell 19% after President Trump announced significant tariffs on April 2 but has since recovered slightly due to a 90-day pause on the most aggressive duties. Experts anticipate short-term volatility and uncertainty, with a 45% chance of recession within a year, while long-term consequences may include reduced economic growth and living standards. Analysts warn that these tariffs could represent a major policy mistake, leading to economic fragmentation and lasting harm, especially to...

Advanced Micro Devices (AMD -7.42%) experienced a significant stock price decline of 7.4% amid broader market downturns, hitting a low of 10.5% during the session. The drop was influenced by AMD's announcement of an effective ban on sales of its MI308X processor to China, leading to an anticipated $800 million write-down, alongside rising costs due to TSMC's planned 30% price increase on 4nm chips. Additionally, escalating U.S.-China trade tensions and cautious remarks from Federal Reserve...

Cancer-focused biotech NovoCure (NVCR -4.07%) saw its stock price target cut by Wedbush analyst David Nierengarten from $29 to $27, leading to a nearly 5% drop in stock value amidst bearish sentiment. Despite a 21% year-over-year revenue growth in Q4 2024, the company reported a net loss of $0.61 per share, worse than analysts expected. While investors are impatient for positive news, the company remains well-positioned in cancer treatment, suggesting it may be a discount...

Recent stock market volatility has highlighted the telecom sector's stability, with AT&T and Verizon emerging as strong investment options. AT&T is at a pivotal point, focusing on expanding its 5G and fiber-optic networks following a divestment of entertainment assets, projecting $16 billion in free cash flow (FCF) for 2024, while Verizon is also growing its mobile and fiber businesses, pursuing an acquisition to boost broadband connections. Both companies show promise, but AT&T has outperformed in...